- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
8th grade Avg
|
- 10-K Annual report
- 3.1 Certificate of Amendment
- 10.4 1994 Employee Stock Purchase Plan
- 10.5 1998 Stock Option Plan
- 10.7 Form of Agreement Providing Specified Benefits
- 10.15 Lease Agreement Between Registrant and University of Utah
- 10.16 Agreement to Sublease Between Harrison & Star, Inc
- 10.17 Term Sheet Between Mars Discovery District and the Registrant
- 12.1 Computation Ratio of Earnings Available to Cover Fixed Charges
- 21.1 List of Subsidiaries
- 23.1 Consent of Independent Auditors
- 31.1 302 Certification of the CEO
- 31.2 302 Certification of the CFO
- 32 906 Certification of the CEO & CFO
EXHIBIT 23.1
Consent of Independent Auditors
The Board of Directors and Stockholders
NPS Pharmaceuticals, Inc.
We consent to incorporation by reference in the registration statements (Nos. 33-79622, 333-17521, and 333-94269) on Forms S-8 and (Nos. 333-41758, 333-106770 and 333-108612) on Forms S-3 of NPS Pharmaceuticals, Inc. of our report dated February 9, 2004, relating to the consolidated balance sheets of NPS Pharmaceuticals, Inc. and subsidiaries (a development stage enterprise) as of December 31, 2003 and 2002, and the related consolidated statements of operations, stockholders’ equity and comprehensive income (loss), and cash flows for each of the years in the three-year period ended December 31, 2003, and for the period from October 22, 1986 (inception) to December 31, 2003, which report appears in the December 31, 2003 annual report on Form 10-K of NPS Pharmaceuticals, Inc.
Our report refers to a change in the method of amortizing goodwill and intangible assets in 2002.
/s/ KPMG LLP
Salt Lake City, Utah
February 9, 2004